A COMPOSITION COMPRISING COMPONENTS THAT EXHIBIT ANTI-INFLAMMATORY ACTION FORMED FOR SUPPRESSING TYROSINE KINASE
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Tyrosine Kinase Anti-Inflammatory

description: <strong>A COMPOSITION COMPRISING COMPONENTS THAT EXHIBIT ANTI-INFLAMMATORY ACTION FORMED FOR SUPPRESSING TYROSINE KINASE</strong> <strong>Technical Field</strong> The invention relates to a composition comprising the components that exhibit anti-inflammatory action formed for suppressing tyrosine kinase. <strong>State of the Art</strong> Tyrosine kinase is an enzyme that belongs to the family of protein kinases enabling the protein phosphorylation. Since the type of amino acid that undergoes phosphorylation is tyrosine, this enzyme was given the name tyrosine kinase. Tyrosine kinase may transfer phosphate groups from ATP to the tyrosine residues in the proteins. The phosphorylation of the proteins via the kinases plays a significant role in the signal transduction mechanism. Because the signal transduction controls the functions such as the proliferation and apoptosis of the cells, the changes occurring in this mechanism play an important role in the cancer development and metastasis. Tyrosine kinases are classified into 2 groups according to the location where they are present, namely the membrane-located and cytoplasmic. According to the state of the art, the invention no. WO 2001/007440 entitled "Imidazoles and triazoles as anti-inflammatory agents" relates to the compounds of formula (I) which are useful for treating or preventing inflammatory and immune cell-mediated diseases. Further, the invention no. EP1382339B1 entitled "Compositions containing pyrrolo[2,3-d]pyrimidine derivatives" relates to the combinations of one or more anti-inflammatory agent and a compound of the following formula wherein R1, R2 and R3 are as defined above. These are useful therapy as immunosuppressive agents for organ transplants, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases. Further, the invention no. EP1781299B1 entitled "Anti-inflammatory agents" provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder wherein X is -CO-Y-(R1)n or SO2-Y-(R1)n; and Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or is a cycloalkenyl or polycycloalkenyl group. Further, the invention no. EP2205620B1 entitled "Amorphous form of (11beta,16alpha)-9-fluoro-11-hydroxy-16,17-[(1-methylethyliden)bis(oxy)]-21-[[4- [(nitroxy)methyl]benzoyl]oxy]-pregna-1,4-dien-3,20-dione" relates to the technical field of anti-inflammatory compounds, specifically those of a steroid nature, in particular to a new amorphous form of a nitrooxy derivative of a corticosteroid, its pharmaceutical formulations and its use in the treatment or prevention of diseases or symptoms of the skin or mucous membranes. As a result, the presence of the need for a composition for suppressing tyrosine kinase and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art. <strong>Object of the Invention</strong> In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the suppression of Src tyrosine kinase. Another object of the invention is to enable the suppression of cox-2. In order to achieve the aforesaid advantages, the invention is a composition for suppressing tyrosine kinase, said composition being obtained by the components selected from the group comprising (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one, 99-1% of (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration. <strong>Detailed Description of the Invention</strong> The invention is a composition comprising the components that exhibit anti-inflammatory action formed for suppressing tyrosine kinase. The composition according to the invention enables the suppression of Src tyrosine kinase and the suppression of cox-2. The composition according to the invention contains (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one, 99-1% of (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one. Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight: 1-99% (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one, 99-1% (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one. The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations. Said invention also encompasses the use of said composition for suppressing tyrosine kinase and the manufacture thereof for this purpose. <strong>CLAIMS</strong> A composition for suppressing tyrosine kinase, said composition being obtained by the components selected from the group comprising (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one, 99-1% of (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one that are used individually or in combinations. A composition according to Claim 1 characterized in that it comprises 1-99% by weight (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one. A composition according to Claim 1 characterized in that it comprises 99-1% by weight (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one. Use of the components according to Claims 1 to 3 obtained individually or in combinations selected from the group consisting of (4E)-1-(2,2-hydroxyphenyl)-3-(3,4-dichlorophenyl)-4-propen-2-one, 99-1% of (2E)-2-(2,3-epoxyphenyl)-46-(2,2-dihydroxyphenyl)-6-propen-2-one for the manufacture of a composition for suppressing tyrosine kinase. <strong>ABSTRACT</strong> <strong>A COMPOSITION COMPRISING COMPONENTS THAT EXHIBIT ANTI-INFLAMMATORY ACTION FORMED FOR SUPPRESSING TYROSINE KINASE</strong> The invention relates to a composition comprising the components that exhibit anti-inflammatory action formed for suppressing tyrosine kinase